肝加欣预防抗结核药物性肝炎的临床观察  

The clinical observation of ganjiaxin prevention of anti-tuberculosis drug drug-induced hepatitis

作　　者：李文洪[1] 周渊[1] 唐晓琦[1] 

机构地区：[1]江苏省宜兴市人民医院感染科,214200

出　　处：《临床合理用药杂志》2011年第17期28-29,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨肝加欣对抗结核药物所致肝损害的预防作用。方法将180例结核病患者随机分为治疗组和对照组,各90例。在抗结核治疗的基础上,治疗组给予肝加欣治疗,对照组不使用任何保肝药物。治疗后比较2组肝损害发生率。结果治疗组肝损害发生率为5.6%低于对照组的27.8%,差异有统计学意义(P<0.01)。结论应用肝加欣能够显著降低使用抗结核药物所致肝损害的发生率,可有效避免药物性肝炎的发生。Objective To discuss the prevention effect of ganjiaxin on the anti-tuberculosis drug induced liver damage.Methods 180 cases patients with tuberculosis were randomly divided into treatment group and control group,each of 90 cases.On the basis of anti-tuberculosis drug treatment,treatment group were given ganjiaxin,control group without used any liver protection drug.After treatment,compared the incidence of liver damage of two groups.Results The incidence of liver damage of treatment group（5.6%） was lower than that of control group（27.8%）（P0.01）.Conclusion Application of ganjiaxin can significant reduct the incidence of anti-tuberculosis drug induced liver damage,and can effectively prevent the occurrence of drug-induced hepatitis.

关 键 词：肝加欣 结核 肝炎 药物性 

分 类 号：R595.3[医药卫生—内科学]